12 February 2024.
|
16 |
Role-play.
Anencephaly |
|
17 |
Role-play.
Complaint.
Mis-filed combined Ds test report |
|
18 |
EMQ.
Kangaroo
care |
|
19 |
EMQ.
WOMAN
trial |
16. Anencephaly. Role-players: Mary G,
Navya T.
Candidate’s instructions.
You are an SpR5 and running the ante-natal clinic – your
consultant has been called to help a consultant colleague with an emergency on
the labour unit and is not available for advice.
You are about to see Jean Hathersage. She is 25 years old
and had a 10-week scan last week that showed anencephaly. She stated that she
did not want TOP. She was counselled, given information leaflets and asked to
return to the antenatal clinical today for further discussion.
Your task is to conduct that discussion.
17. Complaint.
Mis-filed combined Ds test report. Role-players: Karuna J, Jess C.
Candidate's Instructions.
You are the SpR in the ante-natal clinic. The consultant
has been called to the labour ward to help with a case of placenta accreta and
you have been put in charge of the clinic.
Mrs Jones had a “combined test” at 11 weeks which gave a
risk of Down’s syndrome of 1: 40. The report was filed in the notes in error by
a clerk without being shown to any of the medical or midwifery staff.
She attended today for the routine 20-week scan. The
ultrasonographer found the report in the notes, realised that no action had
been taken, informed the patient and made arrangements for her to see you
urgently.
18. Kangaroo care.
Question 1.
Which, if any, of
the following are true in relation to kangaroo care?
Option list.
|
A. |
skin-to-skin contact between
mother and baby is a key component |
|
B. |
rooming-in is a key component |
|
C. |
exclusive breastfeeding is a key
component |
|
D. |
carrying the baby in a sling
anterior to the maternal chest is a key component |
|
E. |
carrying the baby in a sling on
the mother’s back is a key component |
|
F. |
carrying the baby in a sling on
the mother’s chest or back is a key component |
|
G. |
carrying the baby in a sling
with skin-to-skin contact with the mother is a key component |
Question 2.
Which, if any, of the following are proven benefits of Kc?
Option list.
|
A. |
↓ neonatal mortality |
|
B. |
↓
neonatal morbidity |
|
C. |
↑
breastfeeding rates |
|
D. |
↑ head circumference growth |
|
E. |
↓
hypothermia |
|
F. |
↑
mother-baby bonding |
|
G. |
↓
necrotising enterocolitis |
|
H. |
↓ neonatal intra-ventricular
haemorrhage |
|
I. |
↓ neonatal sepsis |
|
J. |
↑
neonatal weight gain |
|
K. |
↓
postnatal depression |
|
L. |
↑ psychomotor development at 12
months |
19. WOMAN Trial.
Question
1. What does the acronym “WOMAN” mean? There is no option list.
Question
2. Which condition and drug were the subjects of the trial?.
Question
3. What were the main outcomes of the trial?
Question
4. Which, if any, of the following were in the WHO’s response
to the outcomes?
Option list.
|
D |
the drug to be stored at room temperature |
|
A |
the drug to be used for all pregnant women |
|
B |
the drug to be used prophylactically |
|
C |
the drug to be used orally |
|
F |
the drug to be used within 6 hours |
|
E |
drug manufacturers to be asked to reduce the cost to facilitate
use in developing countries |
Question
5. Which, if any, of the following are true about the WOMAN-2
trial?
Option list.
|
D |
the trial does not exist |
|
A |
the drug to be used for all pregnant women |
|
B |
the drug to be used prophylactically |
|
C |
the drug to be used intravenously |
|
F |
the drug to be used within 6 hours |
|
E |
hysterectomy will be included in the outcomes |
Question
6. Which, if any, of the following are true about the WOMAN-PharmacoTXA
trial?
Option list.
|
A |
the trial does not exist |
|
B |
the drug to be used for all pregnant women |
|
C |
oral v i.m. use will be compared |
|
D |
oral v i.v. use
will be compared |
|
E |
i.m. v. i.v. use will be compared |
|
F |
none of the above |
No comments:
Post a Comment